ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Panel Member at Inflammasome Therapeutics Summit 2021
Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field
ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor (IC 100), which has potential to treat a broad range of inflammatory diseases
WESTON, Fla., Sept. 9, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited panel member at the Inflammasome Therapeutics Summit 2021. The virtual conference is being held November 16-18, 2021.
Mr. Glover and the other panel members, Paul Ashton, President & CEO of Inflammasome Therapeutics, and Anil K. Goyal, CEO & Chairperson of IMMvention Therapeutix, will address thought-provoking topics including:
- Key learnings from recent progress and failures
- Drivers of inflammasome therapeutics development
- Market opportunity and untapped clinical areas
- Bottlenecks in inflammasome therapeutics clinical success
The panel discussion will take place:
Date: Wednesday, November 17th
Time: 9:00-9:30 am ET
Event Registration Link: Inflammasome Therapeutics Summit 2021
To learn more about ZyVersa and its inflammasome ASC inhibitor, IC 100, please request a one-on-one virtual meeting.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS), with potential to treat other kidney diseases. For more information, please visit www.zyversa.com.
SOURCE ZyVersa Therapeutics, Inc.
Share this article